CD3D and PRKCQ work together to discriminate between B-cell and T-cell acute lymphoblastic leukemia

Comput Biol Med. 2016 Oct 1;77:16-22. doi: 10.1016/j.compbiomed.2016.07.004. Epub 2016 Jul 11.


Different therapeutic methods have been developed for the B-cell and T-cell subtypes of acute lymphoblastic leukemia (ALL). The identification of molecular biomarkers that can accurately discriminate between B-cell and T-cell ALLs will facilitate the quick determination of therapeutic plans, as well as reveal the intrinsic mechanisms underlining the two different ALL subtypes. This study computationally screened the high-throughput transcriptome dataset for multiple candidate biomarkers and verified their discrimination abilities in an independent sample set using quantitative real-time polymerase chain reaction (PCR) technology. Both technologies suggest that the two genes CD3D and PKRCQ together provided a good model for classification of B-cell and T-cell ALLs, whereas the individual genes did not show consistent discrimination between the two ALL subtypes. Supplementary material is available at

Keywords: Acute lymphoblastic leukemia; B-ALL; Biomarker; CD3D; PRKCQ; T-ALL.

MeSH terms

  • Biomarkers, Tumor / genetics*
  • CD3 Complex / genetics*
  • Diagnosis, Differential
  • Gene Expression Profiling
  • Humans
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / diagnosis
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / diagnosis
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma* / genetics
  • Protein Kinase C-theta / genetics*
  • Real-Time Polymerase Chain Reaction
  • Transcriptome / genetics


  • Biomarkers, Tumor
  • CD3 Complex
  • CD3delta antigen
  • PRKCQ protein, human
  • Protein Kinase C-theta